Physician profile

Huitt E Mattox

Gastroenterology (Internal Medicine) · Brunswick, GA

NPI 1548255920

$567.62

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$383.95

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $145.34 2024 Exalt Model D
Medtronic, INC. $141.86 2024 Signia
Abbvie INC. $94.70 2020-2024
Romark Laboratories, Lc $77.16 2019
Olympus America INC. $63.76 2024 Visiglide
Braintree Laboratories, INC. $19.22 2023 Sutab
Takeda Pharmaceuticals U.S.A., INC. $13.95 2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $11.63 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Huitt E Mattox

$567.62

in general payments reported 2019-2025

Years
2019-2024
Top company
Boston Scientific Corporation

https://glasscript.com/doctor/69163/huitt-e-mattox

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.